REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Market Cap
$473.65M
P/E Ratio
-1.9
1Y Stock Return
-51.96%
1Y Revenue Growth
-15.14%
Dividend Yield
0.00%
Price to Book
1.6
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.
SeekingAlpha
Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it prepares for the ARTEMIS study in 2025.
Yahoo
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne), has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data.
Yahoo
The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne gene therapies despite questions about their effectiveness.
Yahoo
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II study of RGX-202, the company's next-generation gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital, and Michael Kelly, PhD, Chief Scientific Officer o
Yahoo
Shareholders will be ecstatic, with their stake up 27% over the past week following REGENXBIO Inc. 's ( NASDAQ:RGNX...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MNOV | -12.06% | $93.19M | +2.15% | 0.00% |
BTCT | -11.45% | $42.61M | +353.33% | 0.00% |
NERV | -10.35% | $14.69M | -58.00% | 0.00% |
DT | -10.16% | $15.40B | -1.30% | 0.00% |
CHD | -10.06% | $27.18B | +19.50% | 1.03% |
PRPO | -9.40% | $9.10M | -13.65% | 0.00% |
HRL | -8.75% | $16.30B | -8.38% | 3.81% |
ADBE | -7.98% | $219.93B | -18.23% | 0.00% |
CBOE | -7.73% | $21.46B | +15.84% | 1.11% |
PG | -7.70% | $402.15B | +14.14% | 2.33% |
VERX | -7.56% | $7.99B | +89.70% | 0.00% |
PGR | -7.54% | $149.10B | +57.29% | 0.45% |
HIHO | -7.53% | $8.63M | 0.00% | 6.12% |
FTNT | -6.55% | $69.59B | +72.67% | 0.00% |
TKO | -6.43% | $10.62B | +67.14% | 0.00% |
CPB | -5.95% | $12.96B | +7.08% | 3.40% |
ACIC | -5.76% | $631.49M | +58.21% | 0.00% |
BAH | -5.45% | $17.62B | +9.13% | 1.47% |
CARV | -5.45% | $8.48M | -8.79% | 0.00% |
TW | -5.10% | $28.66B | +42.39% | 0.29% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LMT | 0.04% | $126.40B | +18.99% | 2.36% |
KMB | -0.05% | $45.22B | +11.57% | 3.58% |
VHC | -0.08% | $19.06M | -38.36% | 0.00% |
IMNN | 0.09% | $10.02M | -22.89% | 0.00% |
CYCN | -0.16% | $4.77M | -16.19% | 0.00% |
FAT | -0.30% | $89.30M | -11.53% | 10.73% |
AMZN | -0.35% | $2.15T | +42.19% | 0.00% |
GLP | 0.38% | $1.77B | +51.33% | 5.50% |
PAYC | 0.46% | $12.12B | +21.78% | 0.69% |
META | 0.51% | $1.42T | +66.51% | 0.27% |
RNR | -0.52% | $13.74B | +23.09% | 0.58% |
NHTC | 0.53% | $61.83M | +0.19% | 14.81% |
SEAT | -0.55% | $478.73M | -52.29% | 0.00% |
CHKP | 0.55% | $19.20B | +20.74% | 0.00% |
CRWD | 0.57% | $86.61B | +69.05% | 0.00% |
K | 0.57% | $27.77B | +52.50% | 2.79% |
SYPR | 0.58% | $32.23M | -26.32% | 0.00% |
EG | -0.59% | $15.92B | -8.98% | 2.02% |
INSP | -0.60% | $5.28B | +27.64% | 0.00% |
TPST | 0.64% | $37.75M | -77.59% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 46.89% | $2.09B | -9.52% | 0.00% |
DNLI | 45.30% | $3.50B | +33.66% | 0.00% |
CRSP | 45.21% | $4.01B | -30.49% | 0.00% |
ALEC | 44.95% | $377.04M | -19.46% | 0.00% |
PRTA | 44.71% | $756.01M | -56.52% | 0.00% |
SUNS | 41.61% | $105.89M | +35.31% | 1.37% |
PGEN | 40.74% | $228.91M | -28.00% | 0.00% |
RCKT | 40.45% | $1.20B | -39.83% | 0.00% |
AMPH | 38.95% | $2.10B | -23.00% | 0.00% |
EDIT | 38.67% | $204.72M | -75.49% | 0.00% |
REAL | 38.42% | $473.87M | +93.72% | 0.00% |
VYGR | 38.36% | $287.88M | -21.46% | 0.00% |
MEI | 38.18% | $326.37M | -60.53% | 6.06% |
ACAD | 37.94% | $2.70B | -27.80% | 0.00% |
ALLO | 37.88% | $444.50M | -24.82% | 0.00% |
MNKD | 37.35% | $1.89B | +84.91% | 0.00% |
CRDF | 36.97% | $133.97M | +127.83% | 0.00% |
INVX | 36.93% | $1.11B | -26.36% | 0.00% |
MCFT | 36.87% | $344.65M | -0.29% | 0.00% |
SANA | 36.42% | $526.91M | -41.15% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.83% | $388.04M | 1.43% |
USDU | -21.04% | $201.97M | 0.5% |
VIXY | -20.69% | $195.31M | 0.85% |
UUP | -19.99% | $309.25M | 0.77% |
CTA | -11.17% | $350.27M | 0.78% |
EQLS | -9.00% | $76.08M | 1% |
WEAT | -7.09% | $120.27M | 0.28% |
BSCO | -6.90% | $2.35B | 0.1% |
TAIL | -6.03% | $67.98M | 0.59% |
GBIL | -5.89% | $5.60B | 0.12% |
KCCA | -5.83% | $220.51M | 0.87% |
CLOI | -5.49% | $715.40M | 0.4% |
UNG | -4.89% | $908.80M | 1.06% |
KMLM | -4.57% | $353.87M | 0.9% |
MINT | -4.52% | $11.62B | 0.35% |
CORN | -4.14% | $61.12M | 0.2% |
DBMF | -3.18% | $1.02B | 0.85% |
HIGH | -3.11% | $302.78M | 0.51% |
SHYD | -1.91% | $311.50M | 0.35% |
HDRO | -1.86% | $164.26M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 50.55% | $70.59M | 0.5% |
XBI | 49.52% | $6.58B | 0.35% |
PBE | 47.88% | $258.53M | 0.58% |
IBB | 47.58% | $6.66B | 0.45% |
ARKG | 46.62% | $1.13B | 0.75% |
FBT | 45.21% | $1.11B | 0.56% |
RSPA | 44.97% | $273.87M | 0% |
IWC | 44.90% | $933.99M | 0.6% |
DFAT | 44.61% | $11.16B | 0.28% |
XPH | 44.49% | $157.87M | 0.35% |
IJT | 44.43% | $6.64B | 0.18% |
GRPM | 44.43% | $582.50M | 0.35% |
EES | 44.14% | $668.71M | 0.38% |
PTH | 43.91% | $143.31M | 0.6% |
VTWO | 43.88% | $12.38B | 0.1% |
IWM | 43.67% | $75.73B | 0.19% |
SMMD | 43.31% | $1.24B | 0.15% |
IWO | 43.21% | $12.56B | 0.24% |
ESML | 43.15% | $1.90B | 0.17% |
NUSC | 43.12% | $1.27B | 0.31% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JBBB | -0.09% | $1.26B | 0.49% |
DBA | 0.17% | $755.88M | 0.93% |
CANE | 0.23% | $17.72M | 0.29% |
TBIL | -0.23% | $4.38B | 0.15% |
AGZD | 0.69% | $142.76M | 0.23% |
SGOV | -0.74% | $27.53B | 0.09% |
FBY | -1.16% | $127.69M | 0.99% |
BILZ | -1.31% | $563.02M | 0.14% |
BOXX | -1.43% | $4.43B | 0.1949% |
XBIL | -1.47% | $637.70M | 0.15% |
HDRO | -1.86% | $164.26M | 0.3% |
SHYD | -1.91% | $311.50M | 0.35% |
JUCY | 2.35% | $324.29M | 0.6% |
HIGH | -3.11% | $302.78M | 0.51% |
DBMF | -3.18% | $1.02B | 0.85% |
ULST | 3.43% | $535.47M | 0.2% |
DEFI | 3.44% | $13.58M | 0.94% |
IGBH | 3.57% | $93.85M | 0.14% |
SEIX | 3.72% | $268.81M | 0.62% |
FLRN | 4.02% | $2.33B | 0.15% |
Current Value
$9.561 Year Return
Current Value
$9.561 Year Return